Affitope PD01

Drug Profile

Affitope PD01

Alternative Names: Affitope-PD01A; Parkinson's disease vaccine - AFFiRiS; PD-01A; PD01

Latest Information Update: 15 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AFFiRiS
  • Class Antiparkinsonians; Peptide vaccines
  • Mechanism of Action Alpha-synuclein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple system atrophy; Parkinson's disease

Most Recent Events

  • 18 Apr 2017 AFFiRiS completes a phase I trial in Multiple system atrophy (Early-stage disease) in France (SC) (NCT02270489)
  • 07 Sep 2016 Efficacy and Adverse events data from a phase I trial in Parkinson's disease released by AFFiRiS
  • 09 Aug 2016 Affitope® PD01 is still in phase I trials for Parkinson's disease (Early stage disease) in Austria (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top